The novel compound NO-1886 elevates plasma high-density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesteryl ester transfer protein activity-Reference-Cited by-同舟云学术

The novel compound NO-1886 elevates plasma high-density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesteryl ester transfer protein activity

Published:1997-03 Issue:3 Volume:46 Page:257-260
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Tsutsumi Kazuhiko,Inoue Yasuhide,Hagi Akifumi,Murase Toshio

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference13 articles.

1. Current concepts: High-density lipoprotein: The clinical implications of recent studies;Gorden;N Engl J Med,1989

2. High density lipoprotein metabolism;Eisenberg;J Lipid Res,1984

3. Lipoprotein lipase;Eckel,1989

4. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol;Inazu;J Clin Invest,1994

5. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis;Tsutsumi;J Clin Invest,1993

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NO-1886 ameliorates glycogen metabolism in insulin-resistant HepG2 cells by GSK-3β signalling;Journal of Pharmacy and Pharmacology;2011-11-21

2. Activation of lipoprotein lipase increases serum high density lipoprotein 2 cholesterol and enlarges high density lipoprotein 2 particles in rats;European Journal of Pharmacology;2011-10

3. NO-1886 suppresses diet-induced insulin resistance and cholesterol accumulation through STAT5-dependent upregulation of IGF1 and CYP7A1;Journal of Endocrinology;2009-10-08

4. Lipoprotein Lipase Activator NO-1886;Cardiovascular Drug Reviews;2006-06-07

5. NO-1886 (ibrolipim), a lipoprotein lipase–promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats;Metabolism;2006-02